Neurocrine biosciences announces repurchase of convertible notes

San diego , may 24, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) (the "company" or "neurocrine biosciences") today announced that it has entered into separate, privately negotiated transactions (the "agreements") with certain holders of its existing 2.25% convertible senior notes due 2024 (the "2024 notes") to repurchase approximately $179.4 million aggregate principal amount of the 2024 notes for an aggregate repurchase price of an amount of cash estimated to be the sum of (i) approximately $224.0 million, (ii) an amount based in part on the trading price of the company's common stock and (iii) accrued and unpaid interest. the 2024 notes repurchases are expected to close over a period ending on june 14, 2022, subject to customary closing conditions.
NBIX Ratings Summary
NBIX Quant Ranking